AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19432499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 71
Study 19432499 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 71
Study 18159005 — intervention group
Group type: EXPERIMENTAL
Intervention: TOCE+ILT
Number of subjects: 120
Study 18159005 — intervention group
Group type: COMPARATOR
Intervention: TOCE+PEI
Number of subjects: 120
Study 16185316 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg)
Number of subjects: 6
Study 16185316 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol (12.5, 25 and 50 μg kg‐1 h‐1)
Number of subjects: 6
Study 16185316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12468909 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase-heparin (5000 IU)
Number of subjects: 103
Study 12468909 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 103
Study 9481466 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized reminder letters
Number of subjects: 719
Study 9481466 — intervention group
Group type: COMPARATOR
Intervention: Form letter
Number of subjects: 719
Study 9481466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letters)
Number of subjects: 719
Study 7609595 — intervention group
Group type: EXPERIMENTAL
Intervention: [1-13C]palmitic acid
Number of subjects: 6
Study 2228570 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS program (n = 25)
Number of subjects: 50
Study 2228570 — intervention group
Group type: COMPARATOR
Intervention: Library for free reading time (n = 25)
Number of subjects: 50
Study 631971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglicinate
Number of subjects: 50
Study 631971 — intervention group
Group type: COMPARATOR
Intervention: Iothalamate
Number of subjects: 50
Study 31631496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate transparent dressing
Number of subjects: 474
Study 31631496 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 474
Study 28103073 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities Mobilizing for Change on Alcohol (CMCA)
Number of subjects: 0
Study 28103073 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT (school-based universal screening and brief intervention)
Number of subjects: 0
Study 28103073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition (CMCA + CONNECT)
Number of subjects: 0
Study 28103073 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25676588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (120 μg/kg body weight)
Number of subjects: 31
Study 25676588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (initial dose)
Number of subjects: 31
Study 25676588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 31
Study 25676588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25614898 — intervention group
Group type: EXPERIMENTAL
Intervention: Earmuff
Number of subjects: 96
Study 25614898 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 96
Study 25614898 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 22091799 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light LED therapy
Number of subjects: 30
Study 22091799 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control)
Number of subjects: 30
Study 19453305 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH Risk Appraisal Measure
Number of subjects: 642
Study 23427447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid samples
Number of subjects: 125
Study 23427447 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples
Number of subjects: 125
Study 23427447 — intervention group
Group type: COMPARATOR
Intervention: Serum samples
Number of subjects: 125
Study 15232655 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐BMIPP myocardial scintigraphy
Number of subjects: 159
Study 15232655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch between 201Tl and 123I‐BMIPP images
Number of subjects: 159
Study 15232655 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF (<45%) and number of diseased vessels (two or three)
Number of subjects: 159
Study 15232655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding 123I‐BMIPP TDS and mismatch
Number of subjects: 159
Study 11394955 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom education
Number of subjects: 0
Study 11394955 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 0
Study 9316434 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 13
Study 8281538 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 30
Study 8281538 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 3525052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 11
Study 3525052 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection treatment (CIT)
Number of subjects: 11
Study 28937845 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 320 mcg (80 mcg/inhalation, 4 inhalations)
Number of subjects: 72
Study 28937845 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 160 mcg (40 mcg/inhalation, 4 inhalations)
Number of subjects: 72
Study 28937845 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate MDI 320 mcg (80 mcg/inhalation, 4 inhalations)
Number of subjects: 72
Study 27139012 — intervention group
Group type: EXPERIMENTAL
Intervention: FE 999049 (225 IU subcutaneous dosing)
Number of subjects: 24
Study 27139012 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous FSH levels
Number of subjects: 24
Study 25266159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150mg q12h
Number of subjects: 0
Study 25266159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23930726 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc bis-glycinate 15 mg once a day for 3 months
Number of subjects: 100
Study 23930726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19804808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 69
Study 19804808 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN)
Number of subjects: 69
Study 19804808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study 19067260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (n=19)
Number of subjects: 49
Study 19067260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 49
Study 12025375 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-radiation (n = 65)
Number of subjects: 130
Study 12025375 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 65)
Number of subjects: 130
Study 12025375 — intervention group
Group type: EXPERIMENTAL
Intervention: additional stenting
Number of subjects: 130
Study 9755737 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 251
Study 9755737 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of subthreshold depressive symptoms 7 months after initiation of antidepressant therapy
Number of subjects: 251
Study 9755737 — intervention group
Group type: EXPERIMENTAL
Intervention: History of 2 or more episodes of major depression or chronic mood symptoms for 2 years
Number of subjects: 251
Study 9755737 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both risk factors
Number of subjects: 251
Study 7661140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal debracketing using a prototype device with a high heat tip
Number of subjects: 48
Study 7661140 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 premolars not etched or bracketed)
Number of subjects: 48
Study 2670580 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy and TURP
Number of subjects: 200
Study 2670580 — intervention group
Group type: COMPARATOR
Intervention: TURP alone
Number of subjects: 200
Study 1276696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha (25 mg repeated in six hours)
Number of subjects: 1513
Study 1276696 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (200 ml 20% NaCl)
Number of subjects: 1513
Study 1276696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha
Number of subjects: 1513
Study 1276696 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 1513
Study 1276696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1513
Study 31943257 — intervention group
Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under am-fed conditions
Number of subjects: 22
Study 31943257 — intervention group
Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under am-fastened conditions
Number of subjects: 22
Study 31943257 — intervention group
Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under hs dosing
Number of subjects: 22
Study 30703783 — intervention group
Group type: EXPERIMENTAL
Intervention: B4SC anthropometric measurements
Number of subjects: 394
Study 28576782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 146
Study 28576782 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 146
Study 23336348 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue Plasminogen Activator (0.9 mg/kg, maximum dose 90 mg)
Number of subjects: 0
Study 23336348 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion and angiography imaging
Number of subjects: 0
Study 23806461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (RM)
Number of subjects: 364
Study 23806461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture plus RM
Number of subjects: 364
Study 23806461 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 364
Study 21038962 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 144
Study 21038962 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility-toning-balance
Number of subjects: 144
Study 21038962 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 144
Study 20117364 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 364
Study 20117364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive clinical management
Number of subjects: 364
Study 20117364 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 364
Study 20117364 — intervention group
Group type: COMPARATOR
Intervention: Clinically managed treatment
Number of subjects: 364
Study 17622343 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (0.2 mg/kg biweekly)
Number of subjects: 34
Study 17622343 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (0.2 mg/kg biweekly)
Number of subjects: 34
Study 17622343 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (agalsidase alfa and beta)
Number of subjects: 34
Study 15522375 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily atropine
Number of subjects: 168
Study 15522375 — intervention group
Group type: COMPARATOR
Intervention: Weekend atropine
Number of subjects: 168
Study 11297206 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics supraannular Top Hat valve (n = 7)
Number of subjects: 17
Study 11297206 — intervention group
Group type: COMPARATOR
Intervention: Intraannular valve (n = 10)
Number of subjects: 17
Study 11297206 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics supraannular Top Hat valve
Number of subjects: 17
Study 9475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal steroid treatment in preterm babies
Number of subjects: 35
Study 9475315 — intervention group
Group type: COMPARATOR
Intervention: Cord blood lymphocytes from preterm babies (with and without NRDS)
Number of subjects: 35
Study 9475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity (ID50) of lymphocytes for dexamethasone
Number of subjects: 35
Study 9475315 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionality of glucocorticoid receptors (GR)
Number of subjects: 35
Study 7947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 800 micrograms misoprostol
Number of subjects: 150
Study 7947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential doses of 400 micrograms misoprostol administered 2 hours apart
Number of subjects: 150
Study 7947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 150
Study 7947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of prostaglandin (single dose)
Number of subjects: 150
Study 7947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen
Number of subjects: 150
Study 3328682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5 mg kg‐1
Number of subjects: 40
Study 3328682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31340751 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (30 billion CFU of a mixture of six viable strains) taken orally twice daily for six months
Number of subjects: 52
Study 31340751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder vehicle compound of vitamin D (100,000 IU cholecalciferol)
Number of subjects: 15
Study 26903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder vehicle compound of vitamin D
Number of subjects: 15
Study 26903303 — intervention group
Group type: COMPARATOR
Intervention: Oil vehicle compound of vitamin D (100,000 IU cholecalciferol)
Number of subjects: 15
Study 25784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg Q14 days
Number of subjects: 354
Study 25784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 300 mg Q28 days
Number of subjects: 354
Study 25784512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 23300071 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation
Number of subjects: 30
Study 23300071 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Number of subjects: 30
Study 23300071 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous posterior tibial nerve stimulation
Number of subjects: 30
Study 21338539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with chicken breast, rapeseed oil, and salad
Number of subjects: 11
Study 21338539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato alone
Number of subjects: 11
Study 21338539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with chicken breast and rapeseed oil
Number of subjects: 11
Study 21338539 — intervention group
Group type: COMPARATOR
Intervention: Reference food (glucose solution)
Number of subjects: 11
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative combination chemotherapy
Number of subjects: 0
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with S-1 after D2 resection
Number of subjects: 0
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines (capecitabine)
Number of subjects: 0
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with chemotherapy
Number of subjects: 0
Study 19685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0
Study 17267094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 35mg orally
Number of subjects: 0
Study 17267094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14749694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg for 2 days and 100 mg for 4 days)
Number of subjects: 30
Study 14749694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14749694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study 11514085 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trained clinicians using a 3D camera system and pressure algometer in a double-blinded approach.
Number of subjects: 20
Study 11514085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure algometry performed with a double-blinded approach.
Number of subjects: 20
Study 10459508 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric diagnosis
Number of subjects: 0
Study 10459508 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviance from sex role stereotypes
Number of subjects: 0
Study 10459508 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of behaviour displayed
Number of subjects: 0
Study 7514513 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of human growth hormone (Norditropin) in the abdomen
Number of subjects: 9
Study 7514513 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of human growth hormone (Norditropin) in the thigh
Number of subjects: 9
Study 3497572 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d) and ergocalciferol (20 micrograms/d) supplementation for 6 months
Number of subjects: 193
Study 3497572 — intervention group
Group type: COMPARATOR
Intervention: Control group (69 subjects)
Number of subjects: 193
Study 30620981 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based mobile rehabilitation application
Number of subjects: 2
Study 27322571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 380
Study 27322571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 24710321 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma fatty acids profile (specifically arachidonic acid, total omega 3 polyunsaturated fatty acids, docosapentaenoic acid, docosahexaenoic acid, eicosapentaenoic acid + docosahexaenoic acid, eicosapentaenoic acid + docosapentaenoic acid + docosahexaenoic acid, stearidonic acid)
Number of subjects: 2263
Study 23549151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for the treatment of food allergy
Number of subjects: 0
Study 23549151 — intervention group
Group type: COMPARATOR
Intervention: Early allergen exposure for primary prevention of food allergy
Number of subjects: 0
Study 20816006 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite (M)
Number of subjects: 24
Study 20816006 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent drug (P)
Number of subjects: 24
Study 18437464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 25
Study 18437464 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing therapy (TT)
Number of subjects: 25
Study 16955847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar neurolysis and nerve anterior transposition with immediate range of motion (Group B)
Number of subjects: 43
Study 16955847 — intervention group
Group type: COMPARATOR
Intervention: Ulnar neurolysis and nerve anterior transposition with immobilization (Group A)
Number of subjects: 43
Study 16955847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar neurolysis and nerve anterior transposition (both groups)
Number of subjects: 43
Study 16955847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop scoring system (both groups)
Number of subjects: 43
Study 14621035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 20
Study 14621035 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (P.O.) followed by Naltrexone (P.O.)
Number of subjects: 20
Study 11145360 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 195
Study 11145360 — intervention group
Group type: COMPARATOR
Intervention: Fluoride or chlorhexidine varnish treatment
Number of subjects: 195
Study 8598866 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ticlopidine plus aspirin)
Number of subjects: 517
Study 8598866 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin)
Number of subjects: 517
Study 1412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 42 degrees C
Number of subjects: 10
Study 1412114 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment at 31 degrees C
Number of subjects: 10
Study 3871233 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 38
Study 3871233 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin
Number of subjects: 38
Study 3871233 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclacillin
Number of subjects: 38
Study 30121789 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 29
Study 30121789 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (EG)
Number of subjects: 29
Study 30121789 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study 29101421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (INT)
Number of subjects: 1033
Study 29101421 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic control (STD)
Number of subjects: 1033
Study 26945662 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Finasteride daily for 2 weeks before TURP
Number of subjects: 65
Study 26945662 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Finasteride daily for 4 weeks before TURP
Number of subjects: 65
Study 26945662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 65
Study 24626137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI; 10 ± 0.5° C)
Number of subjects: 7